NP will continue to raise only what is needed when it is needed in order to keep dilution to a minimum. After a positive PDUFA decision later this year and/or FDA approval for leronlimab for mild/moderate and/or severe patients, there may be enough free cash flow to not need to raise any money via shares or warrants. The Company has lots of options!

I am curious about the surprise the finance guy had that NP said was coming having to do with the raise of the AS. Anyone have any thoughts?